- Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
- Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
- Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
- Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
- Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
Arrowhead Pharmaceuticals Inc (HDP1:FRA) closed at 28.06, 6.55% above its 52-week low of 26.33, set on Jun 17, 2022.
26.33Jun 17 202266.50Nov 25 2021
Markit short selling activity
|Market cap||3.12bn USD|
|EPS (TTM)||-1.48 |
Data delayed at least 15 minutes, as of Nov 25 2022 07:20 GMT.